PCN116 Cost-Effectiveness of Denosumab Versus Zoledronic Acid (ZA) for the Prevention of Skeletal-related Events (SRE) in Patients with Bone Metastases from Solid Tumors in the Netherlands
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1217
https://www.valueinhealthjournal.com/article/S1098-3015(11)02779-3/fulltext
Title :
PCN116 Cost-Effectiveness of Denosumab Versus Zoledronic Acid (ZA) for the Prevention of Skeletal-related Events (SRE) in Patients with Bone Metastases from Solid Tumors in the Netherlands
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02779-3&doi=10.1016/j.jval.2011.08.1217
First page :
A455
Section Title :
Cancer
Open access? :
No
Section Order :
1174